comparemela.com

Elocta Eloctate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sobi to present new data at ISTH 2023

Sobi will present new scientific data at ISTH 2023, the 31st Congress of the International Society on Thrombosis and Haemostasis. This event, taking place from 24th to 28th June, will be held both. | June 15, 2023

United statesNew zealandSaudi arabiaCamilla sandstromTony hoosElocta eloctateHead of research developmentInternational society on thrombosisChief medicalAntihemophilic factorCanada japanMiddle easternNews publishing

Swedish Orphan Biovitrum AB: New real-world data shows significantly improved prophylactic effectiveness in patients treated with Elocta compared with standard half-life factor VIII

Annualised bleed rate (ABR), injection frequency and factor consumption were significantly lower compared to standard half-life (SHL) FVIII prophylaxis Results demonstrated the superior

United statesUnited kingdomNordrhein westfalenCity ofNew zealandSaudi arabiaAnders ullmanJohannes oldenburgElocta eloctateUniversity clinic in bonnInternational society on thrombosisSobi investor relations teamHaemophilia centreInstitute of experimental haematologyInternational societyProfessor johannes oldenburg

Swedish Orphan Biovitrum AB: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

STOCKHOLM, Sweden, July 10, 2022 /PRNewswire/ Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection

United statesNordrhein westfalenDietmar bergerAnders ullmanElocta eloctateHemophilia joint healthGlobal head of developmentInternational society on thrombosisEuropean commissionDrug administrationSobi investor relations teamThrombosis treatment centerHead of research developmentInternational societyChief medical officerGlobal head

Swedish Orphan Biovitrum AB: Sobi to present new data at ISTH 2022

STOCKHOLM, June 24, 2022 /PRNewswire/ Sobi will present new data at ISTH 2022, the 30th Congress of the International Society on Thrombosis and Haemostasis, taking place online and in London

United statesUnited kingdomCity ofNew zealandSaudi arabiaAnders ullmanElocta eloctatePrnewswire sobiReferral centersInternational society on thrombosisSobi investor relations teamInternational societyChief medical officerReal world experienceNon interventional studyRecombinant factor

Swedish Orphan Biovitrum AB: Sobi: FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A

Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA Designation is based on XTEND-1 phase 3 study data demonstrating a clinically

United statesNordrhein westfalenAnders ullmanJohn reedElocta eloctateEuropean commissionDrug administrationSobi investor relations teamGlobal head of researchHead of research developmentBreakthrough therapyUnited states foodGlobal headChief medical officerOrphan drugFast track

vimarsana © 2020. All Rights Reserved.